Published in Metabolism on February 01, 2009
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | NCT01125449
Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta (2012) 1.89
Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr (2011) 1.45
Evaluation of vitamin C for adjuvant sepsis therapy. Antioxid Redox Signal (2013) 0.94
Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease. World J Nephrol (2014) 0.87
Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney Dis (2015) 0.78
High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One (2015) 0.77
Mass spectrometry and renal calculi. J Med Life (2010) 0.75
Words of wisdom. Re: Oxalic acid excretion after intravenous ascorbic acid administration. Robitaille L, Mamer OA, Miller WH Jr, et al. Eur Urol (2009) 0.75
Intravenous ascorbic acid infusions and oxalate production. Metabolism (2009) 0.75
Ascorbic acid intake and oxalate synthesis. Urolithiasis (2016) 0.75
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
Criteria and recommendations for vitamin C intake. JAMA (1999) 3.32
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008) 2.27
Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int (2003) 2.09
Effect of ascorbic acid consumption on urinary stone risk factors. J Urol (2003) 2.02
Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg (2002) 1.92
Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg (2000) 1.63
Oxalogenesis in parenteral nutrition solution components. Nutrition (1999) 1.51
Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J Parenter Enteral Nutr (2004) 1.49
Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am (2002) 1.21
Analysis of ascorbic acid and dehydroascorbic acid in biological samples. Methods Enzymol (1999) 1.19
Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis (2004) 1.16
The biosynthesis and turnover of oxalate in normal and hyperoxaluric subjects. J Clin Invest (1960) 1.15
Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med (1985) 1.09
Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med (1994) 1.08
Metabolism of L-ascorbic acid-1-C14 in man. J Biol Chem (1958) 1.06
Vitamin C deficiency in dialysis patients--are we perceiving the tip of an iceberg? Nephrol Dial Transplant (2006) 1.05
Compatibility and stability of additives in parenteral nutrition admixtures. Nutrition (1998) 1.04
Secondary oxalosis due to excess vitamin C intake. Kidney Int (2006) 1.00
Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures. Clin Chem (1991) 0.99
Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis (2005) 0.92
Hyperoxaluria and renal insufficiency due to ascorbic acid administration during total parenteral nutrition. Ann Intern Med (1984) 0.91
Light-induced byproducts of vitamin C in multivitamin solutions. Clin Chem (2004) 0.90
Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med (2005) 0.90
Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) (2005) 0.89
Renal failure secondary to massive infusion of vitamin C. JAMA (1984) 0.89
Physical characteristics of total parenteral nutrition bags significantly affect the stability of vitamins C and B1: a controlled prospective study. JPEN J Parenter Enteral Nutr (2002) 0.88
Stability of ascorbate in urine: relevance to analyses for ascorbate and oxalate. Clin Chem (1985) 0.87
Intravenous nutrient therapy: the "Myers' cocktail". Altern Med Rev (2002) 0.84
Biomarkers for establishing a tolerable upper intake level for vitamin C. Nutr Rev (1999) 0.84
Oxalate is overestimated in alkaline urines collected during administration of bicarbonate with no specimen pH adjustment. Clin Chem (1989) 0.81
Oxalogenesis in parenteral nutrition mixtures. Nutrition (1999) 0.81
Influence of multivitamin regimen on urinary oxalate in home parenteral nutrition patients. Nutr Clin Pract (2003) 0.80
Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients. Nat Clin Pract Nephrol (2006) 0.79
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Beyond prejudice: are negative evaluations the problem and is getting us to like one another more the solution? Behav Brain Sci (2012) 18.61
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst (2002) 4.33
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr (2003) 3.34
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 2.50
Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int (2009) 2.46
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood (2009) 2.31
The Kitty Genovese murder and the social psychology of helping: the parable of the 38 witnesses. Am Psychol (2007) 2.23
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Prospective comparison of 3 gamma-probes for sentinel lymph node detection in 200 breast cancer patients. J Nucl Med (2005) 2.04
Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer. Clin Nucl Med (2015) 1.98
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 1.91
Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ (2005) 1.89
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol (2008) 1.67
Human adrenal glands secrete vitamin C in response to adrenocorticotrophic hormone. Am J Clin Nutr (2007) 1.60
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res (2010) 1.57
Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol (2005) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J (2006) 1.53
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma (2011) 1.52
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. Can J Surg (2005) 1.49
Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 1.46
Intravenously administered vitamin C as cancer therapy: three cases. CMAJ (2006) 1.43
Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell (2007) 1.41
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol (2005) 1.40
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leuk Lymphoma (2011) 1.40
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood (2003) 1.38
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene (2005) 1.36
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest (2010) 1.33
Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet (2004) 1.27
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med (2011) 1.27
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25
Lessons learned from the Decision Board: a unique and evolving decision aid. Health Expect (2000) 1.25
Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr Drug Metab (2003) 1.25
Public health surveillance after the 2010 haiti earthquake: the experience of médecins sans frontières. PLoS Curr (2013) 1.21
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene (2004) 1.18
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol (2003) 1.16
6-Bromo-6-deoxy-L-ascorbic acid: an ascorbate analog specific for Na+-dependent vitamin C transporter but not glucose transporter pathways. J Biol Chem (2004) 1.16
Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. Genes Nutr (2007) 1.16
Vitamin C deficiency in a university teaching hospital. J Am Coll Nutr (2008) 1.15
Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A (2014) 1.14
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist (2003) 1.13
Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose. J Biol Chem (2002) 1.13
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg (2006) 1.12
High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol (2005) 1.11
Ascorbic acid supplements and kidney stone risk. JAMA Intern Med (2013) 1.10
Genetic variation in the sodium-dependent vitamin C transporters, SLC23A1, and SLC23A2 and risk for preterm delivery. Am J Epidemiol (2005) 1.08
Standard-dose vs high-dose multivitamin supplements for HIV. JAMA (2013) 1.08
Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol (2004) 1.06
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood (2002) 1.06
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res (2009) 1.06
Cloning and functional characterization of the mouse fructose transporter, GLUT5. Biochim Biophys Acta (2002) 1.05
Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One (2011) 1.05
Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol (2008) 1.02
Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol (2007) 1.01
Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood (2003) 1.01
Arsenic trioxide: mechanisms of action. Semin Hematol (2002) 1.00
Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther (2008) 0.99
Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int (2010) 0.99
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet (2005) 0.98
PqsA is required for the biosynthesis of 2,4-dihydroxyquinoline (DHQ), a newly identified metabolite produced by Pseudomonas aeruginosa and Burkholderia thailandensis. Biol Chem (2007) 0.98
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol (2008) 0.98
Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Res (2013) 0.97
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica (2008) 0.97
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97